PharmaCyte Intangible Assets vs Good Will Analysis
| PMCB Stock | USD 2.16 0.03 1.41% |
PharmaCyte Biotech financial indicator trend analysis is much more than just breaking down PharmaCyte Biotech prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether PharmaCyte Biotech is a good investment. Please check the relationship between PharmaCyte Biotech Intangible Assets and its Good Will accounts. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in PharmaCyte Biotech. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in main economic indicators. For information on how to trade PharmaCyte Stock refer to our How to Trade PharmaCyte Stock guide.
Intangible Assets vs Good Will
Intangible Assets vs Good Will Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of PharmaCyte Biotech Intangible Assets account and Good Will. At this time, the significance of the direction appears to have weak contrarian relationship.
The correlation between PharmaCyte Biotech's Intangible Assets and Good Will is -0.07. Overlapping area represents the amount of variation of Intangible Assets that can explain the historical movement of Good Will in the same time period over historical financial statements of PharmaCyte Biotech, assuming nothing else is changed. The correlation between historical values of PharmaCyte Biotech's Intangible Assets and Good Will is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Intangible Assets of PharmaCyte Biotech are associated (or correlated) with its Good Will. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Good Will has no effect on the direction of Intangible Assets i.e., PharmaCyte Biotech's Intangible Assets and Good Will go up and down completely randomly.
Correlation Coefficient | -0.07 |
| Relationship Direction | Negative |
| Relationship Strength | Insignificant |
Intangible Assets
Non-physical assets possessed by a company, such as patents, trademarks, and copyrights, which provide long-term value.Good Will
An intangible asset that arises when a company acquires another business for more than the fair market value of its net identifiable assets, representing the value of the brand, customer base, and other intangible factors.Most indicators from PharmaCyte Biotech's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into PharmaCyte Biotech current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in PharmaCyte Biotech. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in main economic indicators. For information on how to trade PharmaCyte Stock refer to our How to Trade PharmaCyte Stock guide.At present, PharmaCyte Biotech's Sales General And Administrative To Revenue is projected to increase significantly based on the last few years of reporting. The current year's Enterprise Value Over EBITDA is expected to grow to 2.44, whereas Selling General Administrative is forecasted to decline to about 4.7 M.
PharmaCyte Biotech fundamental ratios Correlations
Click cells to compare fundamentals
PharmaCyte Biotech Account Relationship Matchups
High Positive Relationship
High Negative Relationship
PharmaCyte Biotech fundamental ratios Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Other Current Liab | 816.6K | 552.5K | 499.0K | 458.3K | 527.0K | 467.7K | |
| Total Current Liabilities | 1.0M | 724.8K | 704.4K | 586.6K | 674.6K | 1.2M | |
| Total Stockholder Equity | 5.1M | 6.7M | 89.9M | 72.7M | 83.6M | 87.8M | |
| Retained Earnings | (103.9M) | (107.4M) | (111.6M) | (116.0M) | (104.4M) | (99.1M) | |
| Common Stock Total Equity | 101.3K | 118.6K | 163.9K | 159.0 | 182.85 | 173.71 | |
| Common Stock Shares Outstanding | 1.4B | 1.7B | 15.5M | 19.5M | 22.4M | 21.3M | |
| Other Stockholder Equity | 108.8M | (20.4K) | 201.6M | 188.7M | 217.0M | 227.8M | |
| Total Liab | 1.1M | 724.8K | 704.4K | 586.6K | 674.6K | 640.8K | |
| Common Stock | 163.9K | 159.0 | 2.1K | 2.2K | 2.5K | 2.4K | |
| Total Assets | 6.2M | 7.4M | 90.6M | 73.3M | 84.3M | 88.5M | |
| Net Debt | (819.7K) | (2.2M) | (85.4M) | (68.0M) | (61.2M) | (58.2M) | |
| Accounts Payable | 185.8K | 172.3K | 205.4K | 128.3K | 147.5K | 140.1K | |
| Cash | 894.9K | 2.2M | 85.4M | 68.0M | 78.2M | 82.2M | |
| Cash And Short Term Investments | 2.5M | 2.2M | 85.4M | 68.0M | 78.2M | 82.2M | |
| Liabilities And Stockholders Equity | 6.2M | 7.4M | 90.6M | 73.3M | 84.3M | 88.5M | |
| Total Current Assets | 1.0M | 2.3M | 85.5M | 68.1M | 78.4M | 82.3M | |
| Other Current Assets | (1.4M) | 73.1K | 94.2K | 107.7K | 96.9K | 92.1K | |
| Accumulated Other Comprehensive Income | (21.7K) | (20.4K) | (15.8K) | (23.0K) | (26.5K) | (27.8K) | |
| Net Tangible Assets | 1.5M | 1.5M | 3.1M | 86.4M | 99.3M | 104.3M | |
| Net Invested Capital | 5.2M | 6.7M | 89.9M | 72.7M | 83.6M | 87.8M | |
| Net Working Capital | 6.2K | 1.6M | 84.8M | 67.6M | 77.7M | 81.6M | |
| Capital Stock | 163.9K | 159.0 | 2.1K | 2.2K | 1.9K | 1.8K |
Becoming a Better Investor with Macroaxis
Macroaxis puts the power of mathematics on your side. We analyze your portfolios and positions such as PharmaCyte Biotech using complex mathematical models and algorithms, but make them easy to understand. There is no real person involved in your portfolio analysis. We perform a number of calculations to compute absolute and relative portfolio volatility, correlation between your assets, value at risk, expected return as well as over 100 different fundamental and technical indicators.Build Optimal Portfolios
Align your risk with return expectations
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in PharmaCyte Biotech. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in main economic indicators. For information on how to trade PharmaCyte Stock refer to our How to Trade PharmaCyte Stock guide.Note that the PharmaCyte Biotech information on this page should be used as a complementary analysis to other PharmaCyte Biotech's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Idea Breakdown module to analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes.
Complementary Tools for PharmaCyte Stock analysis
When running PharmaCyte Biotech's price analysis, check to measure PharmaCyte Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy PharmaCyte Biotech is operating at the current time. Most of PharmaCyte Biotech's value examination focuses on studying past and present price action to predict the probability of PharmaCyte Biotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move PharmaCyte Biotech's price. Additionally, you may evaluate how the addition of PharmaCyte Biotech to your portfolios can decrease your overall portfolio volatility.
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. |
Is PharmaCyte Biotech's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of PharmaCyte Biotech. If investors know PharmaCyte will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about PharmaCyte Biotech listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.48) | Return On Assets (0.05) | Return On Equity (0.02) |
The market value of PharmaCyte Biotech is measured differently than its book value, which is the value of PharmaCyte that is recorded on the company's balance sheet. Investors also form their own opinion of PharmaCyte Biotech's value that differs from its market value or its book value, called intrinsic value, which is PharmaCyte Biotech's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because PharmaCyte Biotech's market value can be influenced by many factors that don't directly affect PharmaCyte Biotech's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between PharmaCyte Biotech's value and its price as these two are different measures arrived at by different means. Investors typically determine if PharmaCyte Biotech is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, PharmaCyte Biotech's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.